Market Overview

Array Biopharma Recoups Some Of Its Losses From Sharply Lower Open

Related ARRY
Stifel's ASCO Abstract Cheat Sheet
Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting

Array Biopharma Inc (NASDAQ: ARRY) shares are trading lower by $0.66 (7.2 percent) at $9.90 in Monday's session.

Before the open, the company announced its new drug application for its Binimetinib Monotherapy for the treatment of a rare skin cancer has been withdrawn from the FDA Division of Oncology Products. The company announced it will continue trials for the drug in combination with Encorafenib, with the Phase 3 results to be delivered in mid-2017.

After a much lower open, Array's stock reached $8.93 in the first minute of the session and began to rebound. That low coincides with a pair of lows from January 6 ($8.84) and January 9 ($8.88). So far, the ensuing rally has taken the issue right to the bottom end of Friday's range ($10.25).

At this time, the issue is attempting to avoid it first close under $10.00 since January 11, when it ended that session at $9.42.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (ARRY)

View Comments and Join the Discussion!